Emerging treatments for premature ejaculation: Focus on dapoxetine

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 37-46

  Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dapoxetine; Discontinuation syndrome; Premature ejaculation; Selective serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; DAPOXETINE; FLUOXETINE; FLUVOXAMINE; LIDOCAINE; NATURAL PRODUCT; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRILOCAINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TADALAFIL; TOPICAL AGENT; TRAMADOL; VARDENAFIL;

ANORGASMIA; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DIARRHEA; DISTRESS SYNDROME; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; GAIT DISORDER; HUMAN; IMPOTENCE; INSOMNIA; LATENT PERIOD; LIBIDO DISORDER; MALE; MENTAL DISEASE; NAUSEA; NOTE; PATHOPHYSIOLOGY; PREMATURE EJACULATION; PSYCHOTHERAPY; SELF ESTEEM; SELF REPORT; SEX THERAPY; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; SINGLE DRUG DOSE; SOMNOLENCE; SYNCOPE; VOMITING; WITHDRAWAL SYNDROME;

EID: 68149151891     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Note

References (72)

1. Althof SE. Prevalence, characteristics and implications of premature ejaculation/rapid ejaculation. J Urol. 2006;175(3 Pt 1):842-848.
2. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007;51(3):816-824. (Pubitemid 46097263)
3. Carson C, Gunn K. Premature ejaculation: definition and prevalence. Int J Impot Res. 2006;18(suppl 1):S5-S13.
4. Waldinger MD. Recent advances in the classification, neurobiology and treatment of premature ejaculation. Adv Psychosom Med. 2008;29:50-69.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
6. McMahon CG, Althof SE, Waldinger MD, et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2008;5(7):1590-1606. (Pubitemid 352044417)
7. Dunn KM, Croft PR, Hackett GI. Association of sexual problems with social, psychological, and physical problems in men and women: a cross sectional population survey. J Epidemiol Community Health. 1999;53(3):144-148.
8. Rowland D, Perelman M, Althof S, et al. Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med. 2004;1(2):225-232. (Pubitemid 40424658)
9. Sotomayor M. The burden of premature ejaculation: the patient perspective. J Sex Med. 2005;2(suppl 2):110-1104 (Pubitemid 40740370)
10. Rowland DL, Patrick DL, Rothman M, Gagnon DD. The psychological burden of premature ejaculation. J Urol. 2007;177(3):1065-1070.
11. Patrick DL, Althof SE, Pryor JL, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med. 2005;2(3):358-367.
12. Giuliano F, Patrick DL, Porst H, et al. Premature ejaculation: results from a five-country European observational study. Eur Urol. 2008;53(5):1048- 1057.
13. Porst H, Giuliano F, Patrick DL, et al. Impact of premature ejaculation (PE) on female partners: results from a 5-country European observational study [abstract]. Eur Urol Suppl. 2008;7(3):186.
14. Carson CC, Glasser DB, Laumann EO, West SL, Rosen RC. Prevalence and correlates of premature ejaculation among men aged 40 years and older: a United States nationwide population-based study [abstract]. J Urol. 2003;169(4 suppl):321-322.
15. Moreira ED Jr, Brock G, Glasser DB, et al. Help-seeking behaviour for sexual problems: the Global Study of Sexual Attitudes and Behaviors. Int J Clin Pract. 2005;59(1):6-16. (Pubitemid 40260106)
16. Giuliano F. 5-hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci. 2006;30(2):79-84.
17. Wolters JP, Hellstrom WJ. Current concepts in ejaculatory dysfunction. Rev Urol. 2006;8(suppl 4):S18-S25.
18. Giuliano F, Hellstrom WJG. The pharmacological treatment of premature ejaculation. BJU Int. 2008;102(6):668-675.
19. Barnes T, Eardley I. Premature ejaculation: the scope of the problem. J Sex Marital Ther. 2007;33(2):151-170.
20. McMahon C. The etiology and management of premature ejaculation. Nat Clin Pract Urol. 2005;2(9):426-433.
21. Masters W, Johnson V. Human Sexual Inadequacy. Boston, MA: Little Brown and Co; 1970.
22. Semans J. Premature ejaculation: a new approach. S Med J. 1956;49:353-358.
23. De Amicis LA, Goldberg DC, LoPiccolo J, Friedman J, Davies L. Clinical follow-up of couples treated for sexual dysfunction. Arch Sex Behav. 1985;14(6):467-489 (Pubitemid 16210911)
24. Hawton K, Catalan J, Martin P, Fagg J. Long-term outcome of sex therapy. Behav Res Ther. 1986;24(6):665-675.
25. McCabe MP. Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J Sex Marital Ther. 2001;27(3):259-271. (Pubitemid 32374398)
26. Abdel-Hamid IA, El Naggar EA, El Gilany A-H. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res. 2001;13(1):41-45.
27. Morales A, Barada J, Wyllie MG. A review of the current status of topical treatments for premature ejaculation. BJU Int. 2007;100(3):493-501. (Pubitemid 47205483)
28. Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia. 2002;34(6):356-359. (Pubitemid 35463780)
29. Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int. 2004;93(7):1018-1021. (Pubitemid 38758626)
30. Henry R, Morales A. Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study. Int J Impot Res. 2003;15(4):277-281. (Pubitemid 37101662)
31. Dinsmore WW, Hackett G, Goldmeier D, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int. 2006;99(2):369-375. (Pubitemid 46103119)
32. Choi HK, Xin ZC, Choi YD, Lee WH, Mah SY, Kim DK. Safety and efficacy study with various doses of SS-cream in patients with premature ejaculation in a double-blind, randomized, placebo controlled clinical study. Int J Impot Res. 1999;11(5):261-264.
33. Choi HK, Jung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology. 2000;55(2):257-261.
34. Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176-194. (Pubitemid 27514710)
35. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62(suppl 3):10-21.
36. Chouinard G, Saxena B, Bélanger M-C, et al. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord. 1999;54(1-2):39-48. (Pubitemid 29287671)
37. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998;18(4):274-281. (Pubitemid 28353869)
38. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 1994;151(9):1377-1379. (Pubitemid 24281766)
39. Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002;14(6):502-505. (Pubitemid 36068429)
40. McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol. 1999;161(6):1826-1830. (Pubitemid 29420742)
41. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002;5(2):147-151. (Pubitemid 34662976)
42. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25(3):255-261. (Pubitemid 30641002)
43. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol. 2007;52(5):1331-1339. (Pubitemid 47446018)
44. Mondaini N, Ponchietti R, Muir GH, et al. Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time. Int J Impot Res. 2003;15(3):225-228. (Pubitemid 36928916)
45. McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int. 2006;98(2):259-272.
46. McMahon CG, Stuckey BG, Andersen M, et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med. 2005;2(3):368-375. (Pubitemid 40744377)
47. Salonia A, Maga T, Colombo R, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol. 2002;168(6):2486-2489. (Pubitemid 35402646)
48. Hosseini MM, Yarmohammadi H. Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol Int. 2007;79(1):28-32. (Pubitemid 47051814)
49. Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int. 2008;80(2):162-165.
50. Malavige LS, Jayaratne SD, Kathriarachchi ST, Sivayogan S, Fernando DJ, Levy JC. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med. 2008;5(9):2125-2134.
51. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med. 2008;5(1):188-193.
52. Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol. 2006;26(1):27-31. (Pubitemid 43167087)
53. Clément P, Bernabé J, Gengo P, et al. Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine. Eur Urol. 2007;51(3):825-832. (Pubitemid 46097276)
54. Giuliano F, Bernabe J, Gengo P, Alexandre L, Clement P. Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: comparison with paroxetine. J Urol. 2007;177(1):386-389. (Pubitemid 44879485)
55. Gengo PJ, Giuliano F, McKenna K, et al. Monoaminergic transporter binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation [abstract]. J Urol. 2005;173(4):239.
56. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85(1):11-28.
57. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. 2006;46(3):301-309. (Pubitemid 43260317)
58. Kendirci M, Salem E, Hellstrom WJ. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther Clin Risk Manag. 2007;3(2):277-289. (Pubitemid 46881455)
59. PAXIL® (paroxetine hydrochloride) Tablets and Oral Suspension [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
60. ZOLOFT® (sertraline hydrochloride) Tablets and Oral Concentrate [package insert]. New York, NY: Pfizer Inc; 2005.
61. Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised-controlled trials. Lancet. 2006;368(9539):929-937. (Pubitemid 44331385)
62. McMahon C, Park NC, Zhao Y, Rothman M, Rivas D. Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Oral presentation at: 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine; October 6-10, 2007; Jeju, Korea. Abstract OS05-06.
63. Buvat J, Giuliano F, Tesfaye F, Rothman M, Rivas D. Efficacy and safety of dapoxetine for premature ejaculation (PE): results from a placebo-controlled, double-blind, randomized, parallel-group study in 22 countries [abstract]. Urology. 2007;70(3):15.
64. Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial [published online ahead of print November 19, 2008]. BJU Int. doi:10.1111/j.1464-410X.2008.08165.x.
65. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. The Premature Ejaculation Profile (PEP): validation of self-reported outcome measures for research and practice [published online ahead of print September 12, 2008]. BJU Int. doi:10.1111/j.1464-410X.2008.08041.x.
66. Buvat J, Giuliano F, Tesfaye F, Rothman M, Rivas D. Patient-reported treatment benefit of dapoxetine (DPX) for the treatment of premature ejaculation (PE) in 22 countries [abstract]. J Sex Med. 2008;5(suppl 1):30.
67. Brock G, Buvat J, Giuliano F, et al. Improvement in sexual satisfaction of female partners of men with premature ejaculation (PE) treated with dapoxetine (DPX) [abstract]. J Urol. 2008;179(suppl 4):431-432.
68. Buvat J, Giuliano F, Tesfaye F, Rothman M, Rivas D. Improvement in sexual functioning of female partners of men with premature ejaculation (PE) treated with dapoxetine (DPX) [abstract]. Eur Urol Suppl. 2008;7(3):186.
69. Park NC, McMahon C, Tesfaye F, Zhao Y, Rothman M, Rivas D. Safety and tolerability of dapoxetine for the treatment of premature ejaculation in an Asia-Pacific population. Oral presentation at: 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine; October 6-10, 2007; Jeju, Korea. Abstract OS05-07.
70. Shabsigh R, Pryor JL, Tesfaye F. Dapoxetine for the treatment of premature ejaculation: low incidence of sexual side effects. In: Chen J, Arver S (chairpersons). P-05 Ejaculatory Disorders. J Sex Med. 2007;4(suppl 2):118.
71. Casey R, Tesfaye F, Mudumbi R, Rothman M, Rivas D. Effects of dapoxetine (DPX) for the treatment of premature ejaculation (PE) on the erectile function and scales of mood and affect [abstract]. Eur Urol Suppl. 2008;7(3):186.
72. Giuliano F, Levine SB, Buvat J, et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials [abstract]. Eur Urol Suppl. 2008;7(3):187.